Healthcare & Life Sciences Industry Updates

Google News – FDA (biotech/pharma) External News

Vera Therapeutics wins FDA accelerated approval for Trutakna - The Pharma Letter

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma secures positive FDA feedback for Urcosimod - grafa.com

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

Merck KGaA wins FDA Breakthrough status for enpatoran - The Pharma Letter

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

FDA Orphan Drug and Rare Pediatric Disease designations for tegacorat - The Pharma Letter

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain - Proactive financial news

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study - Stock Titan

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy - PharmaTimes

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

UroGen Pharma (URGN) Receives FDA Clearance for IND of UGN-501 - GuruFocus

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain - Proactive financial news

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial - Stock Titan

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial - Investing.com

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial - Fierce Pharma

news.google.com · 09 Jul 2026

Google News – FDA (biotech/pharma) External News

OKYO Pharma advances urcosimod to Phase 3 trial for neuropathic corneal pain after positive FDA feedback - Pluang

news.google.com · 09 Jul 2026

Google News – Medical Devices External News

Johnson & Johnson highlights diversified healthcare strength. Long-term growth anchored in pharmaceu - AD HOC NEWS

news.google.com · 09 Jul 2026

News & Articles

Cancer Is Rarely Caused By One Mistake: Why Healthcare Professionals Must Improve Public Understanding

Beyond AI: Why Human Empathy Will Remain Healthcare's Most Valuable Skill

Why healthcare providers are sidelining employees amid coronavirus pandemic

For adults with prediabetes, lifestyle intervention lowered risk of developing multiple chronic conditions

New Alzheimer’s blood test may tell when symptoms are around the corner

4 takeaways from MDUFA VI draft agreement

J&J wins FDA approval for dual-energy ablation catheter

Physicians’ wearable data use hampered by reimbursement, workflow barriers: survey

Vacancy: National Consultant (NO C) to strengthen maternal and newborn health systems.

Stanford Health Care Tri-Valley launches hospital expansion - Stanford Medicine

HHSC, UT Southwestern Medical Center celebrate opening of new psychiatric hospital in Dallas - UT Southwestern Medical

Hospital and health system leaders participate in Healthcare of Tomorrow Conference - American Hospital Association

HCA Healthcare hospitals earn 26 Press Ganey Human Experience Awards for patient experience - HCA Healthcare Today

CEO Nancy Brown named to Becker’s Hospital Review’s 2026 “Great Leaders in Healthcare” list - www.heart.org

Enhancing healthcare workers’ safety and well-being through a comprehensive qualitative analysis across hospital settings - Nature

Providers race to scale hospital-at-home before reimbursement changes - Modern Healthcare

One or Two Health Systems Controlled the Entire Market for Inpatient Hospital Care in Nearly Half of Metropolitan Areas in 2024 - KFF

How the hospital-at-home program offers alternative care as demand surges - investigatetv.com

Layoffs, closures tracker: Adventist Health cuts 132 jobs - Modern Healthcare

Experts: Cuts to federal student loans could hurt first generation students, healthcare industry - MPR News

Vera Therapeutics wins FDA accelerated approval for Trutakna - The Pharma Letter

OKYO Pharma secures positive FDA feedback for Urcosimod - grafa.com

Merck KGaA wins FDA Breakthrough status for enpatoran - The Pharma Letter

FDA Orphan Drug and Rare Pediatric Disease designations for tegacorat - The Pharma Letter

OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain - Proactive financial news

FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study - Stock Titan

Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy - PharmaTimes

UroGen Pharma (URGN) Receives FDA Clearance for IND of UGN-501 - GuruFocus

OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain - Proactive financial news

OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial - Stock Titan

OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial - Investing.com

OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com

Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial - Fierce Pharma

OKYO Pharma advances urcosimod to Phase 3 trial for neuropathic corneal pain after positive FDA feedback - Pluang

Johnson & Johnson highlights diversified healthcare strength. Long-term growth anchored in pharmaceu - AD HOC NEWS